Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...
SAN DIEGO and SHANGHAI and SYDNEY, April 30, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announces that the U.S. Food and Drug Administration (FDA) has cleared drug candidate IMG-007 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results